Patients with refractory leukemia or minimal residual disease (MRD) at transplant have increased risk of relapse. Augmentation of irradiation, especially to sites of disease (i.e., bone marrow) is one potential strategy to overcome this risk. We studied the feasibility of radiation dose escalation in high risk patients using total marrow irradiation (TMI) in a phase I dose-escalation trial. Four pediatric and 8 adult patients received conditioning with cyclophosphamide and fludarabine in conjunction with image-guided radiation to the bone marrow at 15 Gy and 18 Gy (in 3 Gy/fractions), while maintaining the total body irradiation (TBI) dose to the vital organs (lungs, hearts, eyes, liver, kidneys) at <13.2 Gy. The biologically effective dose (BED) of TMI delivered to the bone marrow was increased by 62% and 96% at 15 and 18 Gy compared to standard TBI. While excessive dose-limiting toxicity defined by graft failure or excess specific organ toxicity was not encountered, three of six patients experienced treatment-related mortality (TRM) at 18Gy. Thus, we halted enrollment at this dose level and treated an additional 4 patients at 15 Gy. The 1 year OS was 42% (CI 95%, 15–67%) and DFS was 22% (CI 95%, 4–49%). The rate of relapse was 36% (CI 95%, 10–62%) and the non-relapse mortality was 42% (CI 95%, 14–70%). This study shows that dose escalation of TMI to 15 Gy is feasible with acceptable toxicity in pediatric and adult high risk leukemia patients undergoing umbilical cord blood (UCB) and sibling donor transplantation.